Navigation Links
LAB Research announces changes to its Board of Directors
Date:2/9/2009

www.labresearch.com

Toronto Stock Exchange Symbol: LRI

LAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ - LAB Research Inc. ("LRI", "LAB Research" or the "Company") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced the nomination of Mr. Carl A. Spalding as Chairman of its Board of Directors in replacement of Mr. Karsten Skydsgaard who previously communicated a wish to step down of the Board to focus on his other professional obligations.

"On behalf of the Board of Directors, I would like to thank Karsten for his dedication and contribution to LAB Research since our 2006 Initial Public Offering ("IPO"). His expertise, and continuous support toward the Company have played a key role in LRI's development and success," said Mr. Luc Mainville, Chief Executive Officer and President of LAB Research.

Mr. Spalding brings to LRI extensive operational experience and contacts in the global pharmaceutical and contract research organization industries. Mr. Spalding has held numerous senior executive positions such as President and Chief Operating Officer of PAREXEL International Corporation, Executive Vice President and Group President, Healthcare Products Services at Cardinal Health and Vice President and General Manager, Ross Products for Abbott Laboratories.

"I am impressed with the timely execution and completion of the growth and development strategy put forward by the Senior Management team at LRI since its 2006 IPO. I am also confident that the recently adopted measures to insure a swift improvement of the Company's financial performance will prove to be successful and look forward to actively participating in the continued success of LAB Research," commented Mr. Spalding.

"We are very fortunate to have someone of Carl's calibre and with such industry experience and relationships to assume the Chairmanship of LAB Rese
'/>"/>

SOURCE LAB RESEARCH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
2. LAB research to present at upcoming UBS 2009 global healthcare services conference in New York
3. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
4. Heinlein Trust and SpaceX Announce Competition to Promote Research Innovation in Zero Gravity
5. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
6. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
7. ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services
8. 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases
9. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
10. NewCardio Joins the Cardiac Safety Research Consortium
11. Avantium Launches the Crystalline, a New Parallel System for Crystallization Research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5